Lumizyme has been NPHC's covered standard since 2006, and next-generation ERT switch criteria still don't exist.

Pompe disease incidence in GCC is estimated at 1 in 20,000 to 30,000 births, elevated above the global 1 in 40,000 rate by consanguinity, with classic infantile-onset disease concentrated in consanguineous families and late-onset cases managed through adult metabolic disease services at KFSH&RC, KAMC, and AUH. Saudi Arabia added Pompe to its newborn-screening panel in 2021, creating a pre-symptomatic infantile-onset pipeline that anchors alglucosidase alfa as first treatment before any next-generation competitor can enter. NPHC covers enzyme replacement therapy for both infantile- and late-onset disease, and total treated patients across GCC number an estimated 80-120.

Avalglucosidase alfa (Nexviazyme), SFDA-registered in 2022, demonstrated superior six-minute-walk and forced-vital-capacity outcomes to alglucosidase alfa in the COMET trial, but GCC adoption remains nascent: NPHC has not established criteria for switching adequately-responding patients from Lumizyme, so access runs through individual case submission rather than standing formulary approval. Sanofi is pursuing NPHC inclusion for Nexviazyme as a first-line ERT option, which would bypass the switch-criteria requirement entirely. Cipaglucosidase alfa plus miglustat, FDA-approved in 2023, is not yet SFDA-registered, giving Nexviazyme a multi-year runway before a third mechanism arrives.

Next-gen ERT beats the 2006 standard clinically but still can't get a formulary switch.

Five questions this report answers:

Q1 - What NPHC criteria govern switching an adequately-responding LOPD patient to avalglucosidase alfa?

Q2 - How is Saudi Arabia's 2021 newborn-screening expansion changing the infantile-onset ERT pipeline?

Q3 - When will cipaglucosidase alfa plus miglustat reach SFDA registration, and what window does that leave Nexviazyme?

Q4 - Why hasn't Nexviazyme displaced Lumizyme as first-line ERT despite superior COMET trial outcomes?

Q5 - How does individual case submission work today for GCC patients seeking avalglucosidase alfa?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PompeDisease #GCC #RareDisease #EnzymeReplacementTherapy #MarketAccess

Live report page:  https://axlrx.ai/pompe-disease/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/